Hsu, Jonathan Y.
Fulco, Charles P.
Cole, Mitchel A.
Canver, Matthew C.
Pellin, Danilo
Sher, Falak
Farouni, Rick http://orcid.org/0000-0002-3454-2946
Clement, Kendell
Guo, Jimmy A.
Biasco, Luca
Orkin, Stuart H.
Engreitz, Jesse M.
Lander, Eric S.
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
Bauer, Daniel E. http://orcid.org/0000-0001-5076-7945
Pinello, Luca http://orcid.org/0000-0003-1109-3823
Article History
First Online: 30 November 2018
Competing interests
: J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Endcadia, Monitor Biotechnologies (formerly known as Beacon Genomics), Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals. J.K.J. holds equity in EpiLogic Therapeutics. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy, and an inventor on patents and patent applications covering CRISPR-based nucleases and gene regulatory proteins. E.S.L. serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics, and on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he is also affiliated with several nonprofit organizations, including through his service on the Board of Directors of the Innocence Project and Biden Cancer Initiative and the Board of Trustees for the Parker Institute for Cancer Immunotherapy. He has served and continues to serve on various federal advisory committees. The Broad Institute, which E.S.L. directs, holds patents and has filed patent applications on technologies related to other aspects of CRISPR.